Warren Buffett: leans back in his chair "Well, we've all looked at Bristol-Myers Squibb. Let me start with the big question—if we had to own this entire enterprise for 20 years without the ability to sell, would we sleep well at night?"

Charlie Munger: "That depends entirely on whether you're buying a collection of patents or a business system. The pharmaceutical industry has always been what I'd call 'permission to print money—temporarily.' The question is whether BMY has built something more durable than just the current patent portfolio."

Dev Kantesaria: "Charlie's exactly right, and that's why I wouldn't sleep well. I look for businesses where success is inevitable over 10-20 years because of structural advantages. BMY's fate depends on winning the R&D lottery over and over. That's not inevitability—that's educated gambling. Remember how Pfizer's Lipitor franchise evaporated? That's the pattern here."

Robert Vinall: "Dev, I understand your quality focus, but let me push back. The best pharma companies aren't just patent collectors—they build institutional capabilities in drug discovery, clinical development, and commercial execution. BMY's work in immuno-oncology with Opdivo and Yervoy shows they can create durable franchises, not just one-hit wonders."

Pulak Prasad: "Robert makes a fair point about capabilities, but we must consider the evolutionary pressures. The pharmaceutical industry is changing faster than ever. Look at the mRNA disruption from Moderna, the gene therapy advances, the weight loss drugs revolutionizing metabolic disease. BMY's traditional small-molecule expertise might become the buggy whip of medicine."

David Tepper: "Pulak, while that's theoretically concerning, in practice, big pharma has consistently absorbed new technologies. Merck bought into immuno-oncology, Lilly bought into diabetes innovations. BMY has $15 billion in operating cash flow to acquire or partner with the disruptors. This isn't Kodak facing digital photography—it's more like IBM adapting to cloud computing."

Mohnish Pabrai: "David, I'd argue the acquisition track record is mixed. Look at BMY's $13 billion acquisition of MyoKardia—brilliant in hindsight with mavacamten's success. But then look at the $74 billion Celgene acquisition with its Revlimid patent cliff. This management team has shown both brilliance and overpaying."

Warren Buffett: "That Celgene acquisition is worth examining deeper. Charlie and I have seen enough acquisitions to know that the price you pay determines whether you're building or destroying value. But before we get to financials, let's stay qualitative. Dev, you mentioned inevitability—what would make a pharmaceutical company inevitable in your framework?"

Dev Kantesaria: "Warren, I'd point to something like Roche's diagnostics business or Danaher's life sciences platform—businesses where customers are locked into ecosystems. BMY sells discrete molecules. When patents expire, doctors prescribe generics without a second thought. There's no recurring revenue, no switching costs, no ecosystem. That's why I can't see 20 years out."

Charlie Munger: "Dev, you're describing the perfect when good enough exists. In medicine, doctors develop tremendous loyalty to therapies they've seen work. Opdivo created entire treatment protocols that don't disappear when patents expire. The moat isn't in the molecule itself but in the clinical experience and physician comfort."

Pulak Prasad: "Charlie, that physician loyalty has been eroding for decades. Formulary decisions are made by PBMs and insurance companies now, not individual doctors. The economic buyer cares about cost, not clinical nuance. That structural shift fundamentally undermines the traditional pharma moat."

Robert Vinall: "Pulak makes an important point about pricing pressure, but that's exactly why BMY's focus on innovative, hard-to-replicate biologics and cell therapies matters. You can't easily genericize CAR-T therapies. The industry is evolving toward more complex modalities where commercial advantages persist longer."

Mohnish Pabrai: "What worries me is the regulatory environment. The IRA legislation allows Medicare to negotiate drug prices—that's a fundamental change in the rules of the game. We're moving from 'charge what the market will bear' to 'charge what the government will allow.' That changes the entire economic model."

David Tepper: "Mohnish, the market has overreacted to the IRA. Most of BMY's portfolio won't face negotiation for years, and when they do, it's still profitable—just less so. This is typical Washington theater that creates buying opportunities, like the tobacco settlements did decades ago."

Warren Buffett: "Let's transition to the financials now. We've touched on the qualitative—patents, regulation, competition. What does the actual track record show us about this business model's durability?"

Charlie Munger: "The numbers tell a simple story: this business prints cash until it doesn't. Look at the operating cash flow—$15 billion annually. That's the kind of number that gets my attention. But then you see the R&D spending required to maintain it, and you understand this is a See's Candies that needs constant reinvention."

Dev Kantesaria: "Charlie, that R&D requirement is exactly the problem. Look at the 10-year ROIC history—it's all over the place because they're constantly writing off failed acquisitions and R&D. This isn't a business with consistent returns on capital. It's a series of bets, some of which pay enormously and others which zero out."

Robert Vinall: "Dev, if you look through the accounting noise, the core cash generation is remarkably consistent. Even through patent expirations, the company has maintained $10+ billion in annual free cash flow for over a decade. That suggests a portfolio effect that smooths out individual patent cliffs."

Pulak Prasad: "Robert, the cash flow is impressive, but look at where it goes: $5-6 billion annually in R&D just to stay in place, another $4-5 billion in acquisitions to fill pipelines. This is a business on a treadmill where you have to run faster each year just to maintain position. Contrast that with a true compounder like Moody's that spends pennies on R&D and earns 40% ROIC."

David Tepper: "Pulak, you're comparing apples to oranges. Pharma has always been capital intensive—the question is whether you get returns on that capital. BMY's recent R&D productivity has actually improved—look at the success rate of their clinical trials compared to industry averages. They're getting better at the drug development game."

Mohnish Pabrai: "David, improved R&D efficiency helps, but the economics are still brutal. For every Opdivo, there are a dozen failures. The current EPS of $2.97 doesn't reflect the true earning power because they're in between major patent expirations and new product launches. This is why I never trust single-year earnings in pharma."

Warren Buffett: "Mohnish raises the crucial point about normalized earnings. If we try to look through the cycle, what would you consider BMY's sustainable earning power?"

Charlie Munger: "The $15 billion operating cash flow is the real number, not the accounting EPS. After maintenance capex and necessary R&D, you're probably looking at $8-10 billion of discretionary cash flow. The question is what management does with it."

Dev Kantesaria: "Charlie, that cash flow is declining though. Revlimid was generating $12 billion annually at peak and now it's fading fast. The new products aren't replacing that entirely. This is the phama paradox: the cash flow looks stable in aggregate, but underneath, individual products are cycling from billions to zero."

Robert Vinall: "Dev, that's too pessimistic. Look at the new product portfolio—Sotyktu, Camzyos, mavacamten. These aren't incremental improvements—they're practice-changing therapies with patent protection into the 2040s. The innovation engine is actually accelerating."

Pulak Prasad: "Robert, I'd be more convinced if the company had a better track record of organic innovation versus acquired innovation. Most of their recent successes came from acquisitions, not internal R&D. That suggests the internal culture may not be as innovative as the portfolio suggests."

David Tepper: "Pulak, in today's pharma world, the ability to identify and integrate external innovation is itself a competitive advantage. BMY's b business development team has shown both good and bad judgment, but overall, they've been net acquirers of value."

Mohnish Pabrai: "Which brings us to valuation. At $54.65 per share, we're paying approximately 18 times that depressed $2.97 EPS number. But if we normalize earnings to, say, $4-5 per share based on the cash flow generation, we're at 11-14 times earnings with a 4.6% dividend yield. That's not expensive for a business with these margins."

Warren Buffett: "So let's move to final verdicts. At current prices, would you buy, hold, or avoid?"

Dev Kantesaria: "I'm avoiding. Conviction 9/10. The lack of visibility beyond 5-7 years violates my requirement for inevitable compounding. This business could be brilliant or broken in 15 years, and I can't tell which. I'd rather pay up for certainty."

David Tepper: "I'm holding neutral, conviction 6/10. This is a defensive large-cap with strong liquidity and predictable demand patterns. The 4.6% dividend and low beta make it suitable for tactical allocation, but not for my best ideas portfolio."

Robert Vinall: "Also holding, conviction 7/10. BMY could become a compounding machine if R&D reinvestment yields durable new franchises. The business has scale and cash generation, but needs to demonstrate it can innovate organically at scale."

Pulak Prasad: "Holding as well, conviction 8/10. I view BMY as an evolutionary survivor in a slow-changing industry. Despite impairments, the firm's core cash engine remains intact, and they've navigated patent cliffs before."

Mohnish Pabrai: "I'd buy lower, conviction 6/10. I treat BMY as an asymmetric bet during panic periods. Despite 2024's loss, operating cash flow of $15 billion confirms survival value far above market fears. But I'd want a bigger margin of safety—maybe $45-50 range."

Charlie Munger: "I'm with Mohnish—buy lower, conviction 7/10. This is a solid, understandable enterprise if you focus on cash flows rather than scientific complexity. The business earns high margins and generates cash, but I'd want a better price given the patent uncertainty."

Warren Buffett: "I'll round us out with buy lower, conviction 8/10. The cash economics are compelling—$15 billion operating cash flow and >70% gross margins confirm real pricing power. But the patent cliffs and R&D demands mean I'd want a lower entry point to account for the uncertainty."

Warren Buffett: surveys the room "Let me try to synthesize where we've landed after this discussion. On the qualitative side, we have fundamental disagreement about whether pharmaceutical businesses can be true long-term compounders. Dev makes the compelling point that discrete patent expiration creates unavoidable cliffs, while Robert and I see that the portfolio approach and continued innovation can create a durable enterprise.

The financial evidence shows both sides of this story—magnificent cash generation of $15 billion annually, but requiring constant reinvestment just to maintain position. That $8.18 in free cash flow per share tells us this is a valuable business, but the erratic ROIC at 12.4% confirms it's not a seamless compounding machine.

Where we largely converge is that the current price at $54.65 doesn't offer enough margin of safety for the risks involved. Four of us would want to see a lower price—in the $45-50 range—where the downside is protected by the cash generation and dividend, while the upside captures any R&D successes.

The three who would hold rather than buy lower seem to acknowledge the quality but want to see more evidence of organic innovation before committing capital. Only Dev would avoid entirely, based on his rigorous requirement for 20-year visibility.

What's clear is that BMY sits in that uncomfortable middle ground—too high quality to short, not certain enough to back up the truck. As Charlie would say, it's not a cinch, but it's not a catastrophe either. For patient capital willing to accept the pharma cycle, it could work out fine, but you'd want to buy it like you'd buy a bond—at a price that gives you comfort in the yield and downside protection."